Exosome-based microRNA biomarkers for early detection of pancreatic cancer
Official title: Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer
Funded at Beckman Research Institute/city of Hope · NIH-11535266 · Data updated 2026-11-12
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 1, 2017 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $13,525 |
| NIH project number | 3U01CA214254-09S1 |
| Project ID | NIH-11535266 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults at risk or suspected of having pancreatic cancer who could provide blood samples for biomarker analysis.
✕Less likely to help
Individuals without pancreatic cancer or those not contributing to the biomarker development may not benefit.
What this research studies
This project aims to use microRNAs carried in exosomes found in blood to detect pancreatic cancer at an earlier, more treatable stage. Researchers will analyze cf-miRNAs and exo-miRNAs with advanced computer methods to develop a reliable biomarker panel. If successful, this could one day lead to a simple blood test that helps identify PDAC before symptoms worsen. Participants would contribute blood samples for analysis, with the goal of creating a robust diagnostic signature.
Why it matters
Potential benefit: If successful, the test could enable earlier detection of pancreatic cancer, improving treatment options and survival chances.
How similar studies have gone: Previous work has shown promise for cf-miRNA and exosome-based biomarkers in PDAC, with ongoing refinement needed to reach clinical use.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Goel, Ajay — Beckman Research Institute/city of Hope
- Study coordinator: Goel, Ajay
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
-
Bioelectrical signals in pancreatic cancer cells: shaping immune responses
This grant explores how electrical signals inside pancreatic cancer cells affect how the immune system can fight the cancer, with the goal of making immunotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.